Bentazon (Basagran)

CASRN 25057-89-0

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (20 pp, 145 K) last updated: 03/02/1998

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
3.0 x10-2 Hematologic Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs NOAEL (ADJ): 3.2
mg/kg-day
100 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (20 pp, 145 K) last updated: 03/02/1998
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (20 pp, 145 K) last updated: 03/02/1998

WOE Characterization Framework for WOE Characterization
E (Evidence of non-carcinogenicity for humans) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Not likely to be carcinogenic to humans Proposed Guidelines for Carcinogen Risk Assessment (US EPA, 1996)
Basis:
  • Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, Bentazon would be classified as evidence of non-carcinogenicity for humans, or a Group E chemical. Under EPA's proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), Bentazon would be characterized as not likely to be carcinogenic to humans by any route of exposure.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (20 pp, 145 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (20 pp, 145 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.